Apolipoprotein E in Cardiovascular Diseases: Novel Aspects of an Old-fashioned Enigma

Archives of Medical Research

Volumn 49, Issue 8, 2018, Pages 522-529

  Liehn, Elisa A ^a,b,c   Ponomariov, Victor ^a,b   Diaconu, Rodica ^b   Streata, Ioana ^b   Ioana, Mihai ^b   Crespo Avilan, Gustavo E ^d,e   Hernández Reséndiz, Sauri ^d,e   Cabrera Fuentes, Hector A ^d,e,f,g,h  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e DEPARTMENT OF CARDIOLOGY   (Singapore)

^f KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^g SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^h JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

ApoE polymorphism; Cardiovascular diseases; Cell membrane; Lipids

Indexed keywords

APOLIPOPROTEIN E; CARRIER PROTEIN; ISOPROTEIN; LIPID;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; LIPID MEMBRANE; LIPID TRANSPORT; NONHUMAN; PLEIOTROPY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN POLYMORPHISM; REVIEW; GENETIC POLYMORPHISM; LIPID METABOLISM; METABOLISM; NEUROLOGIC DISEASE; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; TRANSPORT AT THE CELLULAR LEVEL;

APOLIPOPROTEINS E; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; HUMANS; LIPID METABOLISM; LIPIDS; NERVOUS SYSTEM DISEASES; POLYMORPHISM, GENETIC; PROTEIN ISOFORMS; RISK FACTORS;

EID: 85053072421     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2018.08.008     Document Type: Review

References (97)

1. Mahley, R.W., Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240 (1988), 622–630.
2. Zannis, V.I., Breslow, J.L., Utermann, G., et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 23 (1982), 911–914.
3. Kraft, H.G., Menzel, H.J., Hoppichler, F., et al. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 83 (1989), 137–142.
4. Driscoll, D.M., Getz, G.S., Extrahepatic synthesis of apolipoprotein E. J Lipid Res 25 (1984), 1368–1379.
5. Zechner, R., Moser, R., Newman, T.C., et al. Apolipoprotein E gene expression in mouse 3T3–L1 adipocytes and human adipose tissue and its regulation by differentiation and lipid content. J Biol Chem 266 (1991), 10583–11058.
6. Beisiegel, U., Weber, W., Ihrke, G., et al. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 341 (1989), 162–164.
7. Cooper, A.D., Hepatic clearance of plasma chylomicron remnants. Semin Liver Dis 12 (1992), 386–396.
8. Mahley, R.W., Huang, Y., Rall, S.C. Jr., Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 40 (1999), 1933–1949.
9. Dong, L.M., Parkin, S., Trakhanov, S.D., et al. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol 3 (1996), 718–722.
10. Dong, L.M., Weisgraber, K.H., Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem 271 (1996), 19053–19057.
11. Grundy, S.M., Pasternak, R., Greenland, P., et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100 (1999), 1481–1492.
12. Cohn, J.S., Tremblay, M., Boulet, L., et al. Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism. Atherosclerosis 169 (2003), 63–70.
13. Davignon, J., Gregg, R.E., Sing, C.F., Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8 (1988), 1–21.
14. Dallongeville, J., Roy, M., Leboeuf, N., et al. Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. Arterioscler Thromb 11 (1991), 272–278.
15. Wang, X.L., McCredie, R.M., Wilcken, D.E., Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol 15 (1995), 1030–1034.
16. Kessler, C., Spitzer, C., Stauske, D., et al. The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol 17 (1997), 2880–2884.
17. Luc, G., Bard, J.M., Arveiler, D., et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb 14 (1994), 1412–1419.
18. Stengard, J.H., Weiss, K.M., Sing, C.F., An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E. Hum Genet 103 (1998), 234–241.
19. Lehtinen, S., Lehtimaki, T., Sisto, T., et al. Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis 114 (1995), 83–91.
20. Stengard, J.H., Zerba, K.E., Pekkanen, J., et al. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 91 (1995), 265–269.
21. Miettinen, T.A., Vanhanen, H., Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes. Atherosclerosis 105 (1994), 217–226.
22. Ballantyne, C.M., Herd, J.A., Stein, E.A., et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 36 (2000), 1572–1578.
23. Breslow, J.L., Mouse models of atherosclerosis. Science 272 (1996), 685–688.
24. Daugherty, A., Mouse models of atherosclerosis. Am J Med Sci 323 (2002), 3–10.
25. Simsekyilmaz, S., Cabrera-Fuentes, H.A., Meiler, S., et al. Role of extracellular RNA in atherosclerotic plaque formation in mice. Circulation 129 (2014), 598–606.
26. Simsekyilmaz, S., Cabrera-Fuentes, H.A., Meiler, S., et al. Response to letter regarding article “Role of extracellular RNA in atherosclerotic plaque formation in mice”. Circulation 130 (2014), e144–e145.
27. Cabrera-Fuentes, H.A., Alba-Alba, C., Aragones, J., et al. Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside. Basic Res Cardiol, 111, 2016, 7.
28. Cabrera-Fuentes, H.A., Aragones, J., Bernhagen, J., et al. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research. Basic Res Cardiol, 111, 2016, 69.
29. Wachbroit, R., The question not asked: the challenge of pleiotropic genetic tests. Kennedy Inst Ethics J 8 (1998), 131–144.
30. Ulrich, V., Konaniah, E.S., Herz, J., et al. Genetic variants of ApoE and ApoER2 differentially modulate endothelial function. Proc Natl Acad Sci U S A 111 (2014), 13493–13498.
31. Kothapalli, D., Castagnino, P., Rader, D.J., et al. Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222. Atherosclerosis 227 (2013), 65–71.
32. Flork, L., Jouanel, P., Lusson, J.R., et al. Influence of alleles of apolipoprotein E on restenosis after coronary angioplasty in women. Arch Mal Coeur Vaiss 91 (1998), 1475–1479.
33. Liehn, E.A., Zernecke, A., Postea, O., et al. Chemokines: inflammatory mediators of atherosclerosis. Arch Physiol Biochem 112 (2006), 229–238.
34. Liehn, E.A., Postea, O., Curaj, A., et al. Repair after myocardial infarction, between fantasy and reality: the role of chemokines. J Am Coll Cardiol 58 (2011), 2357–2362.
35. Ong, S.B., Hernandez-Resendiz, S., Crespo-Avilan, G.E., et al. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther 186 (2018), 73–87.
36. Allan, L.L., Hoefl, K., Zheng, D.J., et al. Apolipoprotein-mediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells. Blood 114 (2009), 2411–2416.
37. Braesch-Andersen, S., Paulie, S., Smedman, C., et al. ApoE production in human monocytes and its regulation by inflammatory cytokines. PLoS One, 8, 2013, e79908.
38. van den Elzen, P., Garg, S., Leon, L., et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437 (2005), 906–910.
39. Zhang, H.L., Wu, J., Zhu, J., The role of apolipoprotein E in Guillain-Barre syndrome and experimental autoimmune neuritis. J Biomed Biotechnol, 2010, 2010, 357412.
40. Miyata, M., Smith, J.D., Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nature Genet 14 (1996), 55–61.
41. Raffai, R.L., Apolipoprotein E regulation of myeloid cell plasticity in atherosclerosis. Curr Opin Lipidol 23 (2012), 471–478.
42. Murphy, A.J., Akhtari, M., Tolani, S., et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 121 (2011), 4138–4149.
43. Murry, C.E., Jennings, R.B., Reimer, K.A., Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986), 1124–1136.
44. Murry, C.E., Jennings, R.B., Reimer, K.A., New insights into potential mechanisms of ischemic preconditioning. Circulation 84 (1991), 442–445.
45. Ferdinandy, P., Myocardial ischaemia/reperfusion injury and preconditioning: effects of hypercholesterolaemia/hyperlipidaemia. Br J Pharmacol 138 (2003), 283–285.
46. Hausenloy, D.J., Barrabes, J.A., Botker, H.E., et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol, 111, 2016, 70.
47. Li, G., Tokuno, S., Tahep ld, P., et al. Preconditioning protects the severely atherosclerotic mouse heart. Ann Thorac Surg 71 (2001), 1296–1303 discussion 303–304.
48. Jurkovicova, D., Goncalvesova, E., Sedlakova, B., et al. Is the ApoE polymorphism associated with dilated cardiomyopathy?. Gen Physiol Biophys 25 (2006), 3–10.
49. Siwik, D.A., Kuster, G.M., Brahmbhatt, J.V., et al. EMMPRIN mediates beta-adrenergic receptor-stimulated matrix metalloproteinase activity in cardiac myocytes. J Mol Cell Cardiol 44 (2008), 210–217.
50. Bell, R.D., Winkler, E.A., Singh, I., et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485 (2012), 512–516.
51. Seizer, P., Schonberger, T., Schott, M., et al. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis 209 (2010), 51–57.
52. Jin, Z.G., Lungu, A.O., Xie, L., et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 24 (2004), 1186–1191.
53. Satoh, K., Nigro, P., Matoba, T., et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 15 (2009), 649–656.
54. Seizer, P., Ungern-Sternberg, S.N., Schonberger, T., et al. Extracellular cyclophilin A activates platelets via EMMPRIN (CD147) and PI3K/Akt signaling, which promotes platelet adhesion and thrombus formation in vitro and in vivo. Arterioscler Thromb Vasc Biol 35 (2015), 655–663.
55. Orchard, T.J., Eichner, J., Kuller, L.H., et al. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol 4 (1994), 40–45.
56. Guangda, X., Bangshun, X., Xiujian, L., et al. Apovarepsilon(4) allele increases the risk for exercise-induced silent myocardial ischemia in non-insulin-dependent diabetes mellitus. Atherosclerosis 147 (1999), 293–296.
57. Liberopoulos, E., Siamopoulos, K., Elisaf, M., Apolipoprotein E and renal disease. Am J Kidney Dis 43 (2004), 223–233.
58. Chuang, K.I., Leung, B., Hsu, N., et al. Heparin protects against septic mortality via apoE-antagonism. Am J Surg 202 (2011), 325–335.
59. Huebbe, P., Dose, J., Schloesser, A., et al. Apolipoprotein E (APOE) genotype regulates body weight and fatty acid utilization-Studies in gene-targeted replacement mice. Mol Nutr Food Res 59 (2015), 334–343.
60. Deelen, J., Beekman, M., Uh, H.W., et al. Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age. Hum Mol Genet 23 (2014), 4420–4432.
61. Nebel, A., Kleindorp, R., Caliebe, A., et al. A genome-wide association study confirms APOE as the major gene influencing survival in long-lived individuals. Mech Ageing Dev 132 (2011), 324–330.
62. Yue, L., Mazzone, T., Endogenous adipocyte apolipoprotein E is colocalized with caveolin at the adipocyte plasma membrane. J Lipid Res 52 (2011), 489–498.
63. Kim, W.S., Elliott, D.A., Kockx, M., et al. Analysis of apolipoprotein E nuclear localization using green fluorescent protein and biotinylation approaches. Biochem J 409 (2008), 701–709.
64. Leabu, M., The still valid fluid mosaic model for molecular organization of biomembranes: accumulating data confirm it. Discoveries, 1, 2013, e7.
65. Nicolson, G.L., Update of the 1972 Singer-Nicolson Fluid-Mosaic Model of Membrane Structure. Discoveries, 1, 2013, e3.
66. Singer, S.J., Nicolson, G.L., The fluid mosaic model of the structure of cell membranes. Science 175 (1972), 720–731.
67. Igbavboa, U., Hamilton, J., Kim, H.Y., et al. A new role for apolipoprotein E: modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. J Neurochem 80 (2002), 255–261.
68. Zachowski, A., Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem J 294 (1993), 1–14.
69. Wood, W.G., Igbavboa, U., Muller, W.E., et al. Cholesterol asymmetry in synaptic plasma membranes. J Neurochem 116 (2011), 684–689.
70. Nishizuka, Y., Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9 (1995), 484–496.
71. Hayashi, H., Igbavboa, U., Hamanaka, H., et al. Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 13 (2002), 383–386.
72. Das, M., Das, D.K., Lipid raft in cardiac health and disease. Curr Cardiol Rev 5 (2009), 105–111.
73. Elezaby, A., Sverdlov, A.L., Tu, V.H., et al. Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload. J Mol Cell Cardiol 79 (2015), 275–283.
74. Abdurrachim, D., Ciapaite, J., Wessels, B., et al. Cardiac diastolic dysfunction in high-fat diet fed mice is associated with lipotoxicity without impairment of cardiac energetics in vivo. Biochim Biophys Acta 1842 (2014), 1525–1537.
75. Christoffersen, C., Bollano, E., Lindegaard, M.L., et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 144 (2003), 3483–3490.
76. Glenn, D.J., Wang, F., Nishimoto, M., et al. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension 57 (2011), 216–222.
77. Wassall, S.R., Brzustowicz, M.R., Shaikh, S.R., et al. Order from disorder, corralling cholesterol with chaotic lipids. The role of polyunsaturated lipids in membrane raft formation. Chem Phys Lipids 132 (2004), 79–88.
78. Maguy, A., Hebert, T.E., Nattel, S., Involvement of lipid rafts and caveolae in cardiac ion channel function. Cardiovasc Res 69 (2006), 798–807.
79. Goldstein, D.S., Neuroscience and heart-brain medicine: the year in review. Cleve Clin J Med 77:Suppl 3 (2010), S34–S39.
80. Okada, Y., Ito, Y., Aida, J., et al. Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int 54 (2004), 682–687.
81. Wang, X., Noroozian, Z., Lynch, M., et al. Strains of Pathological Protein Aggregates in Neurodegenerative Diseases. Discoveries, 5, 2017, e78.
82. Emamzadeh, F.N., Aojula, H., McHugh, P.C., et al. Effects of different isoforms of apoE on aggregation of the alpha-synuclein protein implicated in Parkinson's disease. Neurosci Lett 618 (2016), 146–151.
83. Ellis, C.E., Murphy, E.J., Mitchell, D.C., et al. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol 25 (2005), 10190–10201.
84. Colom-Cadena, M., Gelpi, E., Charif, S., et al. Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol 72 (2013), 1203–1212.
85. Gallardo, G., Schluter, O.M., Sudhof, T.C., A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nature Neurosci 11 (2008), 301–308.
86. Lau, A., Bourkas, M., Lu, Y.Q.Q., et al. Amyloids and their Possible Influence on Alzheimer Disease. Discoveries, 5, 2017, e79.
87. Chauhan, N.B., Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease. J Lipid Res 44 (2003), 2019–2029.
88. Ltic, S., Perovic, M., Mladenovic, A., et al. Alpha-synuclein is expressed in different tissues during human fetal development. J Mol Neurosci 22 (2004), 199–204.
89. Masliah, E., Mallory, M., Veinbergs, I., et al. Alterations in apolipoprotein E expression during aging and neurodegeneration. Prog Neurobiol 50 (1996), 493–503.
90. Li, L., Zhang, H., Wang, W., et al. Comparative proteomics reveals abnormal binding of ATGL and dysferlin on lipid droplets from pressure overload-induced dysfunctional rat hearts. Sci Rep, 6, 2016, 19782.
91. Heeren, J., Grewal, T., Laatsch, A., et al. Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J Biol Chem 279 (2004), 55483–55492.
92. Venanzoni, M.C., Giunta, S., Muraro, G.B., et al. Apolipoprotein E expression in localized prostate cancers. Int J Oncol 22 (2003), 779–786.
93. Panin, L.E., Russkikh, G.S., Polyakov, L.M., Detection of apolipoprotein A-I, B, and E immunoreactivity in the nuclei of various rat tissue cells. Biochemistry (Mosc) 65 (2000), 1419–1423.
94. Theendakara, V., Peters-Libeu, C.A., Spilman, P., et al. Direct Transcriptional Effects of Apolipoprotein E. J Neurosci 36 (2016), 685–700.
95. Liu, Q., Chen, Y., Auger-Messier, M., et al. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 110 (2012), 1077–1086.
96. Cappetta, D., Esposito, G., Piegari, E., et al. SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy. Int J Cardiol 205 (2016), 99–110.
97. Elliott, D.A., Kim, W.S., Jans, D.A., et al. Apoptosis induces neuronal apolipoprotein-E synthesis and localization in apoptotic bodies. Neurosci Lett 416 (2007), 206–210.